OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) major shareholder Jennifer Pritzker sold 302,369 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the sale, the insider owned 6,201,764 shares in the company, valued at $130,299,061.64. The trade was a 4.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
OrthoPediatrics Stock Performance
Shares of KIDS opened at $21.56 on Friday. The company has a 50-day simple moving average of $21.97 and a 200-day simple moving average of $19.02. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $562.93 million, a PE ratio of -12.83 and a beta of 0.99. OrthoPediatrics Corp. has a 52-week low of $14.42 and a 52-week high of $26.74.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. The firm had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. Equities research analysts predict that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.
Institutional Trading of OrthoPediatrics
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on the company. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. BTIG Research raised their price target on OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Piper Sandler restated an “overweight” rating and issued a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Finally, Needham & Company LLC increased their price objective on OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $26.44.
Check Out Our Latest Report on KIDS
OrthoPediatrics Company Profile
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Featured Stories
- Five stocks we like better than OrthoPediatrics
- Feed to Feat: Can Meta Unlock the AI Agent Cash Machine?
- Chime Finds Its Stride With a $590M Deal That Could Reshape Its Banking Model
- IBM and Lockheed Martin Turn a Swiss Defense Deal Into a Quantum Computing Bet
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
